.Attribute Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, people along with metastatic stomach lumps who acquired biomarker-matched therapies based on distributing growth DNA profiling showed a more significant clinical perk than those acquiring incomparable treatment.